What is the dosing regimen for diltiazem (calcium channel blocker) in the management of supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diltiazem Dosing for SVT

For acute SVT management, administer diltiazem 0.25 mg/kg (approximately 15-20 mg for average adults) IV over 2 minutes, followed by a second dose of 0.35 mg/kg (20-25 mg) after 15 minutes if needed, then maintain with continuous infusion at 5-15 mg/hour titrated to heart rate. 1, 2, 3

Initial IV Bolus Dosing

  • First dose: 0.25 mg/kg (15-20 mg) administered over 2 minutes 1, 2, 3
  • Second dose (if needed): 0.35 mg/kg (20-25 mg) given 15 minutes after the first dose if no therapeutic response occurs 1
  • Conversion to sinus rhythm typically occurs within 2-3 minutes of administration, with maximal heart rate reduction in 2-7 minutes 3, 4
  • The 0.25 mg/kg dose achieves 100% conversion in AV nodal reentry tachycardia and 81-90% conversion in orthodromic reciprocating tachycardia 5, 4

Maintenance Infusion

  • Start continuous infusion at 5 mg/hour, titrate up to 15 mg/hour based on heart rate response 1, 2
  • Infusion maintains at least 20% heart rate reduction in 83% of patients over 24 hours 3
  • Upon discontinuation, heart rate reduction may persist for 0.5 to >10 hours (median 7 hours) 3

Critical Contraindications

Absolutely avoid diltiazem in these situations:

  • Pre-excited atrial fibrillation/flutter (WPW syndrome or accessory pathways conducting to ventricles) - may accelerate ventricular response and cause hemodynamic collapse 1, 2, 3
  • Second or third-degree AV block without functioning pacemaker 1, 2, 3
  • Decompensated heart failure or severe LV dysfunction - negative inotropic effects worsen cardiac output 1, 2
  • Hypotension or cardiogenic shock 2, 3
  • Sick sinus syndrome without pacemaker 2

Monitoring Requirements

  • Continuous ECG monitoring is mandatory during administration 1, 3
  • Frequent blood pressure measurements throughout infusion 1, 3
  • Defibrillator and resuscitation equipment must be immediately available 2, 3

Common Adverse Effects

  • Hypotension is the most frequent adverse effect (occurring in 7-11% of patients), though usually short-lived lasting 1-3 hours 3, 5
  • Only 3.2% of patients require intervention (IV fluids or Trendelenburg positioning) for blood pressure support 3
  • Bradycardia occurs in approximately 10-15% of patients 2, 6
  • Symptomatic hypotension requiring dose adjustment occurs in only 6% of patients 4

Clinical Pearls and Pitfalls

  • Adenosine remains first-line for stable PSVT due to its ultra-short half-life; use diltiazem when adenosine fails or is contraindicated 2
  • If the first 0.25 mg/kg bolus fails, the second 0.35 mg/kg bolus succeeds in the majority of remaining patients 7
  • Never combine diltiazem with beta-blockers acutely - the overlapping longer half-lives can cause profound bradycardia and heart block 1, 2
  • In hemodynamically unstable patients, skip medications entirely and proceed directly to synchronized cardioversion 2
  • Diltiazem works by slowing AV nodal conduction and increasing AV nodal refractoriness, making it effective only when the AV node is part of the reentrant circuit 2, 4
  • One critical pitfall: In patients with atrial fibrillation and WPW, diltiazem can shorten the RR interval from 240 ms to 180 ms, potentially triggering ventricular fibrillation 8

Mechanism of Action

  • Diltiazem prolongs AV nodal refractoriness and slows AV nodal conduction 4
  • It has no effect on accessory pathway refractoriness, which is why it works for orthodromic tachycardia (where the AV node is in the circuit) but is dangerous in pre-excited atrial fibrillation (where the accessory pathway bypasses the AV node) 8, 4

Special Populations

  • Elderly patients (60-91 years): Use the same 0.25 mg/kg dose, but monitor more carefully for bradycardia and hypotension 6
  • In elderly patients, diltiazem achieves sinus rhythm in approximately 50% with atrial fibrillation and slows ventricular rate to <100 bpm in most others 6
  • Bradycardia requiring drug cessation occurs in 16% of elderly patients but reverses rapidly upon discontinuation 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.